3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
870
Carcinoma, Non-Small-Cell Lung
637
Prostatic Neoplasms
516
Multiple Myeloma
443
Neoplasms
425
Leukemia, Myeloid, Acute
380
Lymphoma
357
Melanoma
335
Leukemia
335
Neoplasm Metastasis
322
Lung Neoplasms
308
Lymphoma, Non-Hodgkin
303
Leukemia, Lymphocytic, Chronic, B-Cell
301
Colorectal Neoplasms
282
Ovarian Neoplasms
266
Pancreatic Neoplasms
249
Precursor Cell Lymphoblastic Leukemia-Lymphoma
241
Recurrence
240
Myelodysplastic Syndromes
233
Glioblastoma
212
Hodgkin Disease
201
Lymphoma, Large B-Cell, Diffuse
197
Lymphoma, Follicular
195
Brain Neoplasms
195
Carcinoma, Renal Cell
190
Head and Neck Neoplasms
188
Squamous Cell Carcinoma of Head and Neck
186
Lymphoma, Mantle-Cell
171
Sarcoma
158
Fallopian Tube Neoplasms
139
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Has results
×
DNA Virus Infections
×
Clear all
NCT03487549
2024-11-27
COVE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
56 enrolled
29 charts